Healthcare Industry News: Advaxis
News Release - January 12, 2006
NexMed Appoints Richard J. Berman as C.E.O.
ROBBINSVILLE, NJ--(Healthcare Sales & Marketing Network)--Jan 12, 2006 -- NexMed, Inc. (NasdaqNM:NEXM ), a developer of innovative transdermal products based on its proprietary NexACT® drug delivery technology, today announced that it has appointed Richard J. Berman, who has served on the Board of Directors since 2002, to serve as Chief Executive Officer of the Company, effective immediately. Mr. Berman's business career spans over 35 years of venture capital, management, and merger and acquisition experience. Vivian Liu, who was appointed Executive Vice President and Acting C.E.O. on December 15, 2005, will continue to serve as Executive Vice President and manage the Company's day-to-day operations.Mr. Berman currently serves on the Board of Directors of Dyadic International, Inc., International Microcomputer Software, Inc., Internet Commerce Corporation, MediaBay, Inc., GVI Security Solutions Inc., National Investment Managers, Nayna Networks, Inc. and Advaxis, Inc.
Mr. Berman stated, "As CEO of NexMed, my first mandate is to significantly cut unnecessary expenses and raise equity capital to strengthen the Company's cash reserves. My second mandate is to find licensing partners for Alprox-TD® and Femprox® and analyze our early-stage products for opportunities to replicate the success of our recently licensed anti-fungal nail treatment." Mr. Berman added, "In addition, with the backing of our Board of Directors, we will be aggressive in seeking growth opportunities that would significantly improve shareholder value."
About NexMed, Inc.
NexMed, an innovative drug developer, offers large pharmaceutical companies the opportunity to save considerably on R&D costs, develop new patient-friendly transdermal products, and extend patent lifespans and brand equity, through participation in early stage licensing and development partnerships. NexMed currently has a host of medicines in development, such as treatments for nail fungus, sexual disorders and more, all based on its proprietary NexACT drug delivery technology.
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to its ability to effectively reduce expenses, enter into partnering agreements, raise financing on acceptable terms, pursue growth opportunities, and/or other factors, some of which are outside the control of the Company.
Source: NexMed
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
